H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs

References

• Available from: http://www.who.int/csr/don/archive/year/2016/en/.)
   Google Scholar
• Skowronski DM, Chambers C, Gustafson R, et al. Avian influenza A(H7N9) virus infection in 2 travelers returning from China to Canada, January 2015. Emerg Infect Dis. 2016;22(1):71–74.
   PubMed Web of Science ®Google Scholar
• William T, Thevarajah B, Lee SF, et al. Avian influenza (H7N9) virus infection in Chinese tourist in Malaysia, 2014. Emerg Infect Dis. 2015;21(1):142–145.
   PubMed Web of Science ®Google Scholar
• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888–1897.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature. 2013;499(7459):500–503.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013;341(6144):410–414.
   PubMed Web of Science ®Google Scholar
• Su S, Bi Y, Wong G, et al. Epidemiology, evolution, and recent outbreaks of avian influenza virus in China. J Virol. 2015;89(17):8671–8676.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bi Y, Wang J, et al. Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. J Infect. 2017;75(1):71-75.
   PubMed Web of Science ®Google Scholar
• Zhou X, Li Y, Wang Y, et al. The role of live poultry movement and live bird market biosecurity in the epidemiology of influenza A (H7N9): a cross-sectional observational study in four eastern China provinces. J Infect. 2015;71(4):470–479.
   PubMed Web of Science ®Google Scholar
• Fan M, Huang B, Wang A, et al. Human influenza A(H7N9) virus infection associated with poultry farm, Northeastern China. Emerg Infect Dis. 2014;20(11):1902–1905.
   PubMed Web of Science ®Google Scholar
• Su S, Zhou P, Fu X, et al. Virological and epidemiological evidence of avian influenza virus infections among feral dogs in live poultry markets, China: a threat to human health? Clin Infect Dis. 2014;58(11):1644–1646.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang J, Su W, et al. Relationship between domestic and wild birds in live poultry market and a novel human H7N9 virus in China. J Infect Dis. 2014;209(1):34–37.
   PubMed Web of Science ®Google Scholar
• He F, Chen EF, Li FD, et al. Human infection and environmental contamination with avian influenza A (H7N9) virus in Zhejiang Province, China: risk trend across the three waves of infection. BMC Public Health. 2015;15:931.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang H, Lou X, et al. Living poultry markets in rural area: human infection with H7N9 virus re-emerges in Zhejiang Province, China, in winter 2014. Jl Clin Virol. 2015;70:16–22.
   PubMed Web of Science ®Google Scholar
• Chen Z, Li K, Luo L, et al. Detection of avian influenza A(H7N9) virus from live poultry markets in Guangzhou, China: a surveillance report. PloS One. 2014;9(9):e107266.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu S, Mao H, et al. Surveillance of avian H7N9 virus in various environments of Zhejiang Province, China before and after live poultry markets were closed in 2013–2014. PloS One. 2015;10(8):e0135718.
   PubMed Web of Science ®Google Scholar
• Li Y, Huang XM, Zhao DM, et al. Detection of avian H7N9 influenza A viruses in the Yangtze Delta Region of China during early H7N9 outbreaks. Avian Dis. 2016;60(1 Suppl):118–125.
   PubMed Web of Science ®Google Scholar
• Liu W, Fan H, Raghwani J, et al. Occurrence and reassortment of avian influenza A (H7N9) viruses derived from coinfected birds in China. J Virol. 2014;88(22):13344–13351.
   PubMed Web of Science ®Google Scholar
• Ge FF, Ju HB, Yang DQ, et al. Epidemiological situation and genetic analysis of H7N9 influenza viruses in Shanghai in 2013. Arch Virol. 2014;159(11):3029–3041.
   PubMed Web of Science ®Google Scholar
• Yuan J, Lau EH, Li K, et al. Effect of live poultry market closure on avian influenza A(H7N9) virus activity in Guangzhou, China, 2014. Emerg Infect Dis. 2015;21(10):1784–1793.
   PubMed Web of Science ®Google Scholar
• He Y, Liu P, Tang S, et al. Live poultry market closure and control of avian influenza A(H7N9), Shanghai, China. Emerg Infect Dis. 2014;20(9):1565–1566.
   PubMed Web of Science ®Google Scholar
• Yu H, Wu JT, Cowling BJ, et al. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. Lancet. 2014;383(9916):541–548.
   PubMed Web of Science ®Google Scholar
• Wang D, Yang L, Zhu W, et al. Two outbreak sources of influenza A (H7N9) viruses have been established in China. J Virol. 2016;90(12):5561–5573.
   PubMed Web of Science ®Google Scholar
• Xiang N, Li X, Ren R, et al. Assessing change in avian influenza A(H7N9) virus infections during the fourth epidemic - China, September 2015-August 2016. Morb Mortal Wkly Rep. 2016;65(49):1390–1394.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.who.int/csr/don/20-february-2017-ah7n9-china/en/.)
   Google Scholar
• Iuliano AD, Jang Y, Jones J, et al. Increase in human infections with avian influenza A(H7N9) virus during the fifth epidemic - China, October 2016-February 2017. Morb Mortal Wkly Rep. 2017;66(9):254–255.
   PubMed Web of Science ®Google Scholar
• Hay AJ, Hayden FG. Oseltamivir resistance during treatment of H7N9 infection. Lancet. 2013;381(9885):2230–2232.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Shichinohe S, Nakayama M, et al. Emergence of H7N9 influenza A virus resistant to neuraminidase inhibitors in nonhuman primates. Antimicrob Agents Chemother. 2015;59(8):4962–4973.
   PubMed Web of Science ®Google Scholar
• Yen HL, McKimm-Breschkin JL, Choy KT, et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. mBio. 2013;4(4).
   PubMed Web of Science ®Google Scholar
• Sleeman K, Guo Z, Barnes J, et al. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis. 2013;19(9):1521–1524.
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J Infect Dis. 2015;211(2):249–257.
   PubMed Web of Science ®Google Scholar
• Yen HL, Zhou J, Choy KT, et al. The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets. J Infect Dis. 2014;210(12):1900–1908.
   PubMed Web of Science ®Google Scholar
• Liu Q, Ma J, Strayer DR, et al. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-alpha for infection control and treatment. Expert Rev Anti Infect Ther. 2014;12(2):165–169.
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chesnokov AP, et al. Neuraminidase mutations conferring resistance to oseltamivir in influenza A(H7N9) viruses. J Virol. 2015;89(10):5419–5426.
   PubMed Web of Science ®Google Scholar
• Gillman A, Nykvist M, Muradrasoli S, et al. Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. Antimicrob Agents Chemother. 2015;59(9):5196–5202.
   PubMed Web of Science ®Google Scholar
• Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol. 2011;1(6):563–573.
   PubMed Web of Science ®Google Scholar
• Takashita E, Ejima M, Ogawa R, et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 2016;132:170–177.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977–981.
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981–986.
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 2010;107(2):882–887.
   PubMed Web of Science ®Google Scholar
• Sleeman K, Mishin VP, Deyde VM, et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 2010;54(6):2517–2524.
   PubMed Web of Science ®Google Scholar
• Cao RY, Xiao JH, Cao B, et al. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother. 2014;23(6):237–240.
   PubMedGoogle Scholar
• Watanabe T, Kiso M, Fukuyama S, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013;501(7468):551–555.
   PubMed Web of Science ®Google Scholar
• Tharakaraman K, Subramanian V, Viswanathan K, et al. A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc Natl Acad Sci U S A. 2015;112(35):10890–10895.
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chai N, et al. Human monoclonal antibody 81.39a effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins. J Virol. 2016;90(23):10446–10458.
   PubMed Web of Science ®Google Scholar
• Wilson JR, Guo Z, Reber A, et al. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. Antiviral Res. 2016;135:48–55.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang J, Bao L, et al. Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus. Nat Commun. 2015;6:6714.
   PubMed Web of Science ®Google Scholar
• Tan GS, Leon PE, Albrecht RA, et al. Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog. 2016;12(4):e1005578.
   PubMed Web of Science ®Google Scholar
• Tharakaraman K, Subramanian V, Cain D, et al. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe. 2014;15(5):644–651.
   PubMed Web of Science ®Google Scholar
• Wu XX, Gao HN, Wu HB, et al. Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma. Int J Infect Dis. 2015;41:3–5.
   PubMed Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chesnokov AP, et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis. 2014;210(3):435–440.
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Baranovich T, Marathe BM, et al. Sialic acid-binding protein Sp2CBMTD protects mice against lethal challenge with emerging influenza A (H7N9) virus. Antimicrob Agents Chemother. 2015;59(3):1495–1504.
   PubMed Web of Science ®Google Scholar
• Xu L, Bao L, Li F, et al. Combinations of oseltamivir and fibrates prolong the mean survival time of mice infected with the lethal H7N9 influenza virus. J Gen Virol. 2015;96(Pt 1):46–51.
   PubMed Web of Science ®Google Scholar
• Li C, Li C, Zhang AJ, et al. Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor. PloS One. 2014;9(9):e107966.
   PubMed Web of Science ®Google Scholar